Moderna Inc. (MRNA) reported a profit for the third quarter compared to a loss in the previous year, reflecting surging revenues amid vaccine sales. Total revenue for the quarter surged from last year, resulting from commercial sales of the company's COVID-19 vaccine in the U.S.
However, quarterly earnings per share and revenues missed analysts' expectations. The company also slashed its 2021 product sales and COVID-19 vaccine delivery forecast.
The company slashed its fiscal 2021 product sales outlook to a range of $15.0 billion to $18.0 billion from the prior outlook of $20.0 billion, based on fewer doses for delivery in 2021, shifted to early 2022, and prioritization of deliveries to low-income countries through COVAX and African Union.
The Company expects deliveries of its COVID-19 vaccine in fiscal 2021 to be between 700 million and 800 million doses at the 100 µg dose level, down from the prior outlook of between 800 million and 1 billion doses.
For fiscal 2022, the company has already signed APAs for product sales of approximately $17 billion and options of up to $3 billion, for deliveries in 2022. It also expects commercial booster market sales could be up to $2 billion, Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season.
Based on these revenue drivers, the Company believes 2022 sales could be in the range of $17 billion to $22 billion.
The Board of Directors has also authorized a share repurchase program of up to $1 billion over a two-year period to return excess capital to shareholders.
For the third quarter, the company reported net income of $3.33 billion or $7.70 per share, compared to a net loss of $233 million or $0.59 per share in the prior-year quarter.
On average, 11 analysts polled by Thomson Reuters expected the company to report earnings of $9.05 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter soared to $4.97 billion from last year's $157 million, resulting from commercial sales of the Company's COVID-19 vaccine, and to a lesser extent, grant revenue. Analysts expected revenues of $6.21 billion for the quarter.
Product sales for the quarter were $4.8 billion from sales of the company's COVID-19 vaccine. The increase in grant revenue of $286 million was primarily driven by an increase in revenue from BARDA related to the company's COVID-19 vaccine development.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.